MsC in Biochemistry, PhD for the University Miguel Hernández. 11 years of experience in rare neuromuscular diseases, produced 18 scientific articles and 5 related patents and has been PI in 5 competitive projects.
Dr. Rubén Artero. Advisor and Co-founder
Msc and PhD cum laude in Biochemistry by the University of Valencia. Leader of the translational genomics lab in the UV. Experienced entrepreneur, he is the inventor in 7 patents, 5 of them licensed and co-founded Genera Biotech.
Dr. Pedro Fernández. Director of Operations
Msc in Biochemistry, PhD for the Polytechnic University of Valencia and accredited RTTP by ATTP. 6 years of experience in technology transfer, project management and R&D management.
Description of the advisory board members:
Dr. Ramón Eritja. Institute of Advance Chemistry of Catalonia
Director of the Nucleic Acids Chemistry Group at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC). He was a group leader and director of DNA synthesis facilities at the European Molecular Biology Laboratory (EMBL), Heidelberg (Germany) 1994-1999. He is a CSIC research professor in Barcelona from 2000 to the present. From 2012 to 2017 he was Director of IQAC-CSIC. He has remarkable contacts with several companies dedicated to RNA and DNA synthesis and works as advisor for companies developing therapeutic oligonucleotides.
Dr. Nicholas Johnson. Virginia Commonwealth University.
Nicholas E. Johnson, MD, MSCI, FAAN is an associate professor of Neurology and Human and Molecular Genetics and vice chair of research in Neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester.
His laboratory is focused on identifying the pathogenesis of limb girdle muscular dystrophy, myotonic dystrophy, andfacioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.